What's happening
This bill allows optometrists in New York to prescribe certain oral medications for eye diseases and updates related education and certification requirements.
Why it matters
Expands optometrists’ prescribing authority. The bill allows optometrists to prescribe a limited set of oral medications (specific antibiotics, antiglaucoma agents, and antivirals) for eye diseases, which could make it easier and faster for patients to receive care for certain eye conditions without needing to see an ophthalmologist or primary care provider for a prescription.
Patient safety requirements and referral protocols. The law puts strict limits on the use of these oral medications, such as allowing only a single short-term prescription for antiglaucoma and antiviral drugs, and requiring prompt referral to an appropriate physician in specific cases. This is meant to ensure optometrists work within their scope and that patients with complex or severe conditions are quickly managed by specialists.
Enhanced education and certification standards. To prescribe oral medications, optometrists must complete new, rigorous education and training requirements, including a dedicated certification course and examination focused on pharmacology, drug interactions, and clinical decision-making for ocular disease. This aims to maintain high standards of care and patient safety.
Increased continuing education and regulatory oversight. The bill increases mandatory continuing education hours for optometrists, especially in systemic disease and therapeutic treatment, and introduces new requirements for documentation and departmental approval. This ensures practitioners remain up-to-date on best practices and are subject to stronger oversight, with penalties for non-compliance.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Let Optometrists Prescribe Oral Drugs
Plain English, a few words. Used as the page title.
Sponsors
67 Co-sponsors
- Vivian Cook
- Steven Cymbrowitz
- Thomas Abinanti
- Aileen Gunther
- David Weprin
- Andrew Hevesi
- Albert A. Stirpe
- David DiPietro
- Karl Brabenec
- Patricia Fahy
- William Colton
- Michael J. Norris
- Didi Barrett
- Stacey Pheffer Amato
- Jeffrey Dinowitz
- Kieran Michael Lalor
- Kenneth Zebrowski
- Phil Steck
- Pamela J. Hunter
- Harry B. Bronson
- Michaelle C. Solages
- Crystal Peoples-Stokes
- Carmen De La Rosa
- Brian D. Miller
- Angelo J. Morinello
- Michael J. Fitzpatrick
- Inez E. Dickens
- William Magnarelli
- Victor M. Pichardo
- Angelo Santabarbara
- Joseph Giglio
- Daniel Rosenthal
- Ron Kim
- Robert J. Rodriguez
- Peter Abbate
- Billy Jones
- Clyde Vanel
- David McDonough
- Jeffrion Aubry
- Linda Rosenthal
- Steven Englebright
- Charles Lavine
- Latoya Joyner
- Rebecca Seawright
- Melissa Miller
- Nathalia Fernandez
- Charles Fall
- Mike Reilly
- Karines Reyes
- John Salka
- Monica P. Wallace
- Jonathan Jacobson
- Kimberly Jean-Pierre
- Brian Manktelow
- Al Taylor
- Michael Benedetto
- Steve Stern
- Judy Griffin
- Marianne Buttenschon
- Simcha Eichenstein
- Donna Lupardo
- Carrie Woerner
- Joe Angelino
- John T. McDonald III
- John Lemondes
- Josh Jensen
- Michael Lawler
History
- Substituted by S1519
- Rules report cal.295
- Reported
- Reported referred to rules
- Reported referred to ways and means
- Reported referred to codes
- Referred to higher education
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Let Optometrists Prescribe Oral Drugs
Signed by Governor · Sponsor Jamaal Bailey
Full text
6 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
1921
2021-2022 Regular Sessions
IN ASSEMBLY
January 13, 2021
Introduced by M. of A. PAULIN, COOK, CYMBROWITZ, ABINANTI, GUNTHER, WEPRIN, HEVESI, STIRPE, DiPIETRO, BRABENEC, FAHY, COLTON, NORRIS, BARRETT, PHEFFER AMATO, DINOWITZ, LALOR, ZEBROWSKI, STECK, HUNTER, BRONSON, SOLAGES, PEOPLES-STOKES, DE LA ROSA, B. MILLER,… Show allHide
Introduced by M. of A. PAULIN, COOK, CYMBROWITZ, ABINANTI, GUNTHER, WEPRIN, HEVESI, STIRPE, DiPIETRO, BRABENEC, FAHY, COLTON, NORRIS, BARRETT, PHEFFER AMATO, DINOWITZ, LALOR, ZEBROWSKI, STECK, HUNTER, BRONSON, SOLAGES, PEOPLES-STOKES, DE LA ROSA, B. MILLER, MORINELLO, FITZPATRICK, DICKENS, MAGNARELLI, PICHARDO, SANTABARBARA, J. M. GIGLIO, D. ROSENTHAL, KIM, RODRIGUEZ, ABBATE, JONES, VANEL, McDONOUGH, AUBRY, L. ROSENTHAL, ENGLEBRIGHT, LAVINE, JOYNER, SEAWRIGHT, M. MILLER, FERNANDEZ, FALL, REILLY, REYES, SALKA, WALLACE, JACOBSON, JEAN-PIERRE, MANKTELOW, TAYLOR, BENEDETTO, STERN, GRIFFIN, BUTTENSCHON, EICHENSTEIN, LUPARDO, WOERNER -- Multi-Sponsored by -- M. of A. BARCLAY, BLANKENBUSH, CAHILL, CARROLL, CUSICK, DAVILA, EPSTEIN, FRIEND, GALEF, GOODELL, GOTTFRIED, HAWLEY, PALMESANO, PERRY, QUART, J. RIVERA, TAGUE, THIELE, WALSH -- read once and referred to the Committee on Higher Education
AN ACT to amend the education law, in relation to the use of oral medications by optometrists
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Paragraph (e) of subdivision 1 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:
(e) [Phase one] Topical therapeutic pharmaceutical agents. [Phase one] Topical therapeutic pharmaceutical agents shall mean those drugs which shall be limited to topical application to the surface of the eye for therapeutic purposes and shall be limited to:
(i) antibiotic/antimicrobials;
(ii) decongestants/anti-allergenics;
(iii) non-steroidal anti-inflammatory agents;
(iv) steroidal anti-inflammatory agents;
(v) antiviral agents;
(vi) hyperosmotic/hypertonic agents;
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD02016-01-1
A. 1921 2
(vii) cycloplegics;
(viii) artificial tears and lubricants; and
(ix) immunosuppressive agents.
§ 2. Paragraph (f) of subdivision 1 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:
(f) [Phase two therapeutic] Therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension. [Phase two] Therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension shall mean those drugs which shall be limited to topical application to the surface of the eye and shall be limited to:
(i) beta blockers;
(ii) alpha agonists;
(iii) direct acting cholinergic agents;
(iv) prostaglandin analogs; and
(v) carbonic anhydrase inhibitors.
§ 3. Subdivision 1 of section 7101-a of the education law is amended by adding a new paragraph (g) to read as follows:
(g) Oral therapeutic pharmaceutical agents. Oral therapeutic pharmaceutical agents shall mean those orally administered drugs used for therapeutic purposes solely for the treatment of diseases of the eye and adnexa and shall be limited to:
(i) the following antibiotics:
(1) amoxicillin/clavulanate potassium;
(2) cephalexin;
(3) azithromycin;
(4) sulfamethoxazole/trimethoprim;
(5) doxycycline; and
(6) tetracycline;
(ii) the following antiglaucoma agents used for the management of acute increases in intraocular pressure; provided, however, an optometrist may use or prescribe a maximum of one twenty-four hour prescription and shall immediately refer the patient to a licensed physician specializing in diseases of the eye:
(1) acetazolamide; and
(2) methazolamide; and
(iii) the following antiviral agents used for herpes zoster ophthalmicus; provided an optometrist shall use or prescribe in maximum, one seven-day prescription; provided, however, if a patient is diagnosed with herpes zoster ophthalmicus and has not already been examined by a primary care physician or other appropriate physician for such viral condition, an optometrist shall refer the patient to a licensed primary care physician, licensed physician specializing in diseases of the eye, or other appropriate physician within three days of such diagnosis:
(1) valacyclovir; and
(2) acyclovir.
§ 4. The subdivision heading and paragraph (a) of subdivision 4 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, are amended to read as follows:
[Phase one] Topical therapeutic pharmaceutical agents. (a) Before using or prescribing [phase one] topical therapeutic pharmaceutical agents, each optometrist shall have completed at least three hundred hours of clinical training in the diagnosis, treatment and management of patients with ocular disease other than glaucoma and ocular hypertension, not fewer than twenty-five hours of such training shall have been completed subsequent to June thirtieth, nineteen hundred ninety-three
A. 1921 3
and additionally shall either have taken and successfully passed the treatment and management of ocular diseases portion of the National Board of Examiners in Optometry test or have taken and successfully passed an examination acceptable to the board.
§ 5. Paragraph (b) of subdivision 4 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:
(b) Before using or prescribing [phase two] therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension, an optometrist must be certified for diagnostic and [phase one] topical therapeutic agents and have completed an additional one hundred hours of clinical training in the diagnosis, treatment and management of patients with glaucoma and ocular hypertension, not fewer than twenty-five hours of such training shall have been completed subsequent to July first, nineteen hundred ninety-four, and shall have taken and successfully passed an oral or written examination acceptable by the board.
§ 6. Paragraphs (c) and (d) of subdivision 4 of section 7101-a of the education law are relettered paragraphs (d) and (e) and a new paragraph (c) is added to read as follows:
(c) Before using or prescribing oral therapeutic pharmaceutical agents, an optometrist must be certified to prescribe diagnostic pharmaceutical agents and topical therapeutic and therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension, have completed an oral therapeutic pharmaceutical agent certification course and have passed an examination within five years of the department's approval of the initial certification course or the initial examination, whichever is later provided, however, an optometrist who has commenced the oral therapeutic pharmaceutical agent certification course within the five year time period but has not yet passed an examination shall be allowed to take such examination and become certified after the five year time period provided for in this paragraph has ended.
(i) The curriculum for the oral therapeutic pharmaceutical agent certification course shall include, but not be limited to, instruction in pharmacology and drug interaction in treating ocular disease and be taught through clinical case scenarios and emphasize clinical decision making and shall be no less than forty hours, of which no less than twenty-four hours shall be live instruction.
(ii) Such course shall qualify towards meeting the continuing education per triennial registration requirement pursuant to subdivision seven of this section.
(iii) The examination shall assess the knowledge of materials in the curriculum and reflect the oral therapeutic pharmaceutical agents described in paragraph (g) of subdivision one of this section, and shall be acceptable to the department.
(iv) The initial, and any subsequent, curriculum and examination shall be subject to review and approval by the department.
(v) The requirement for the oral therapeutic pharmaceutical agent certification course and examination shall not apply to those optometrists who graduated from an accredited college of optometry subsequent to January first, two thousand twenty-two and have taken and successfully passed the National Board of Examiners in Optometry examination or an examination acceptable to the department.
§ 7. Subdivision 5 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:
5. Suspension of certification. The department shall suspend the certification for the use and prescribing of [phase one] topical thera-
A. 1921 4
peutic agents of any optometrist who fails to receive certification for [phase two] therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension within three years of having been certified for [phase one] topical therapeutic pharmaceutical agents.
§ 8. The subdivision heading of subdivision 6 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:
Consultation with use of certain topical therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension.
§ 9. Subdivision 7 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:
7. Continuing education. (a) Each optometrist certified to use [phase one or phase two] topical therapeutic pharmaceutical agents and therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension, shall complete a minimum of thirty-six hours of continuing education in the area of ocular disease and pharmacology per triennial registration period. [The education shall be in the area of ocular disease and pharmacology and may include both didactic and clinical components.] Each optometrist certified to use oral therapeutic pharmaceutical agents shall, in addition to the minimum thirty-six hours of continuing education provided for in this subdivision, complete an additional minimum of eighteen hours of continuing education related to systemic disease and therapeutic treatment per triennial registration period. Such educational programs may include both didactic and clinical components and shall be approved in advance by the department [and evidence of the completion of this requirement shall be submitted with each application for license renewal as required by section sixty-five hundred two of this chapter]. Beginning on January first, two thousand twenty-three, all sponsors of continuing education courses seeking advanced approval from the department shall file an application and pay a fee determined by the department in accordance with the regulations of the commissioner. An optometrist subject to the provisions of this subdivision whose first registration date following the effective date of this section occurs less than three years from such effective date, but on or after January first, two thousand twenty-three, shall complete continuing education hours on a prorated basis at the rate of one hour per month for the period beginning January first, two thousand twentythree up to the first registration date thereafter. An optometrist who has not satisfied the mandatory continuing education requirement pursuant to this subdivision shall not be issued a triennial registration certificate by the department and shall not practice unless and until a conditional registration is issued as provided for in paragraph (b) of this subdivision. Continuing education hours taken during one triennium may not be transferred to the subsequent triennium.
(b) The department, in its discretion, may issue a conditional registration to an optometrist who fails to meet the continuing education requirements established in paragraph (a) of this subdivision, but who agrees to make up any deficiencies and complete any additional education which the department may require. The fee for such a conditional registration shall be the same as, and in addition to, the fee for the triennial registration. The duration of such conditional registration shall be determined by the department, but shall not exceed one year. Any optometrist who is notified of the denial of registration for failure to submit evidence, satisfactory to the department, of required continuing education and who practices without such registration may be subject to
A. 1921 5
disciplinary proceedings pursuant to section sixty-five hundred ten of this title.
(c) In accordance with the intent of this section, adjustment to the mandatory continuing education requirement may be granted by the department for reasons of health that are certified by an appropriate health care professional, for extended active duty with the armed forces of the United States, or for other good cause acceptable to the department which may prevent compliance.
(d) An optometrist not engaged in practice, as determined by the department, shall be exempt from the mandatory continuing education requirement upon the filing of a statement with the department declaring such status. Any licensee who returns to the practice of optometry during the triennial registration period shall notify the department prior to reentering the profession and shall meet such continuing education requirements as shall be prescribed by regulations of the commissioner.
(e) Optometrists subject to the provisions of this subdivision shall maintain adequate documentation of completion of acceptable continuing education credits and shall provide such documentation at the request of the department. Failure to provide such documentation upon the request of the department shall be an act of misconduct subject to disciplinary proceedings pursuant to section sixty-five hundred ten of this title.
(f) The mandatory continuing education fee shall be determined by the department. Such fee shall be payable on or before the first day of each triennial registration period, and shall be paid in addition to the triennial registration fee required by subdivision eight of section seventy-one hundred four of this article.
§ 10. The subdivision heading and subparagraph (i) of paragraph (a) of subdivision 8 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, are amended to read as follows:
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.